UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl)
UvA-DARE (Digital Academic Repository)
The puzzle of high-density lipoprotein in cardiovascular prevention
El-Harchaoui, A.
Publication date
2009
Link to publication
Citation for published version (APA):
El-Harchaoui, A. (2009). The puzzle of high-density lipoprotein in cardiovascular prevention.
General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s)
and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open
content license (like Creative Commons).
Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please
let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material
inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter
to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You
will be contacted as soon as possible.
List of Publications 171
list of publications
Karim El Harchaoui; Benoit J. Arsenault; Remco Franssen; Jean-Pierre Despres; G. Kees Hovingh;Erik S.G. Stroes; James D. Otvos; Nicholas J. Wareham; John J.P. Kastelein; Kay-Tee Khaw; S. Matthijs Boekholdt. High density lipoprotein size and particle concentration and coronary risk. Ann Intern Med. 2009; 20;150:84-93.
M Alssema, K El-Harchaoui, RK Schindhelm, M Diamant, G Nijpels, PJ Kostense, T Teerlink, RJ Heine, GM Dallinga-Thie, JA Kuivenhoven, JM Dekker, PG Scheffer.Fasting plasma CETP con-centration is independently associated with the postprandial decrease in HDL-cholesterol concentration following fat-rich meals: The Hoorn postprandial study.
Metabolism (In Press)
K. El Harchaoui, M.E.Visser, J.J.P.Kastelein, E.S.Stroes, G.M.Dallinga-Thie.
Triglycerides and Cardiovascular Risk. Current Cardiology Reviews, 2009, 5, 216-222
El Harchaoui K, Franssen R, Hovingh GK, Bisoendial RJ, Stellaart F, Kuipers F, Kastelein JJ, Kuiven-hoven JA, Stroes ES, Groen AK. Reduced Fecal Sterol Excretion in Subjects with hypoalphalipo-proteinemia. Atherosclerosis. 2009
Karim El Harchaoui, M. Vergeer, Erik S.G. Stroes, Nicholas J. Wareham, John J.P. Kastelein, Jan Albert Kuivenhoven, Kay-Tee Khaw, S. Matthijs Boekholdt. Elevated HDL cholesterol associated with a common mutation in CETP is not associated with a decreased risk for coronary artery disease. (Submitted)
K. El Harchaoui, F. Akdim, J.J.P. Kastelein. Current and future pharmacological options for the management of patients unable to achieve LDL-C goals with statins. American Journal of
Car-diovascular Drugs. 2008; 8(4):233-42.
Vergeer M, El-Harchaoui K, Stroes ES. Cholesterol gene polymorphisms and cardiovascular events. N Engl J Med. 2008; 359:92; author reply 93
El Harchaoui K, van der Steeg WA, Stroes ES, Kuivenhoven JA, Otvos JD, Wareham NJ, Hutten BA, Kastelein JJ, Khaw KT, Boekholdt SM. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007; 49:547-53.
Karim El Harchaoui, Wim A. van der Steeg, Erik S.G. Stroes, John J.P. Kastelein. The role of CETP inhibition in dyslipidemia. Current Atherosclerosis Reports 2007; 9:125-33
Chapt
er 11
172
Fatima Akdim, Karim El Harchaoui, Erik SG Stroes, John JP Kastelein. Antisense apolipoprotein B-100 as novel treatment for hypercholesterolemia: focus on ISIS 301012.
Future Lipidology, 2007; Vol. 2, Pages 387-393.
van der Steeg WA, Boekholdt SM, Stein EA, El-Harchaoui K, Stroes ES, Sandhu MS, Wareham NJ, Jukema JW, Luben R, Zwinderman AH, Kastelein JJ, Khaw KT. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Intern Med. 2007;146:640-8.
Pinedo S, Vissers MN, von Bergmann K, El Harchaoui K, Lutjohann D, Luben R, Wareham NJ, Kastelein JJ, Khaw KT, Boekholdt SM. Plasma levels of plant sterols and the risk of coronary artery disease: the prospective EPIC-Norfolk Population Study.
J Lipid Res. 2007;48:139-44.
Klerkx AH, El Harchaoui K, van der Steeg WA, Boekholdt SM, Stroes ES, Kastelein JJ, Kuivenhoven JA. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis.
Arterioscler Thromb Vasc Biol. 2006;26:706-15. Review.
Van der Steeg WA, El-Harchaoui K, Kuivenhoven JA, Kastelein JJ.
Increasing high-density lipoprotein cholesterol through cholesteryl Ester transfer protein inhibition: a next step in the fight against cardiovascular disease?
Curr Drug Targets Cardiovasc Haematol Disord. 2005;481-8. Review.
Bisoendial RJ, Hovingh GK, El Harchaoui K, Levels JH, Tsimikas S, Pu K, Zwinderman AE, Kuiven-hoven JA, Kastelein JJ, Stroes ES. Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia.
Conference Abstracts 173
conference abstracts
american heart scientific session 2008, new orleans
Presentation: ‘HDL size and HDL particle concentration independently predict coronary artery disease risk in apparently healthy men and women’
american heart scientific session 2007, orlando
Presentation: ’Reduced Fecal Sterol Excretion in Subjects with Low HDL Cholesterol Levels’
international atherosclerosis society 2006, rome
Posterpresentation: ’Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population’
